Macitentan and morbidity and mortality in pulmonary arterial hypertension.
暂无分享,去创建一个
Z. Jing | A. Torbicki | H. Ghofrani | G. Simonneau | O. Sitbon | L. Rubin | R. Souza | T. Pulido | I. Adzerikho | M. Delcroix | N. Galiè | Xiaofeng Zeng | S. Mehta | R. Channick | P. Jansa | F. Le Brun | B. Sastry | L. Perchenet | Camilla Mittelholzer | R. Souza | R. N. Channick | Franck-Olivier Le Brun | L. J. Rubin
[1] M. Clozel,et al. Slow Receptor Dissociation Kinetics Differentiate Macitentan from Other Endothelin Receptor Antagonists in Pulmonary Arterial Smooth Muscle Cells , 2012, PloS one.
[2] P. Gargiulo,et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. , 2012, Journal of the American College of Cardiology.
[3] M. Bolli,et al. The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist. , 2012, Journal of medicinal chemistry.
[4] R. Benza,et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. , 2012, Chest.
[5] H. Palevsky,et al. Validation of 6-Minute Walk Distance as a Surrogate End Point in Pulmonary Arterial Hypertension Trials , 2012, Circulation.
[6] D. Badesch,et al. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. , 2009, Cardiovascular therapeutics.
[7] B. Brundage,et al. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[8] Horst Olschewski,et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. , 2010, Journal of the American College of Cardiology.
[9] R. Barst,et al. Clinical worsening in trials of pulmonary arterial hypertension: results and implications , 2010, Current opinion in pulmonary medicine.
[10] B. Brundage,et al. Tadalafil Therapy for Pulmonary Arterial Hypertension , 2009, Circulation.
[11] T. Fleming,et al. End points and clinical trial design in pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.
[12] M. Bolli,et al. Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist , 2008, Journal of Pharmacology and Experimental Therapeutics.
[13] T. Fleming,et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. , 2008, Annals of internal medicine.
[14] G. Simonneau,et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial , 2008, The Lancet.
[15] B. Wiens,et al. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2 , 2008, Circulation.
[16] R. Barst,et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. , 2006, American journal of respiratory and critical care medicine.
[17] J. Loscalzo,et al. Pulmonary arterial hypertension. , 2004, Annals of medicine.
[18] T. Fleming,et al. Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.
[19] D. Badesch,et al. Ambrisentan therapy for pulmonary arterial hypertension. , 2005, Journal of the American College of Cardiology.
[20] Jack Cuzick,et al. Forest plots and the interpretation of subgroups , 2005, The Lancet.
[21] M. Humbert,et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 , 2004, European Respiratory Journal.
[22] W. Seeger,et al. Inhaled iloprost for severe pulmonary hypertension. , 2002, The New England journal of medicine.
[23] S. Rich,et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.
[24] Avid,et al. BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .
[25] D. Badesch,et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study , 2001, The Lancet.